SG11202104073XA - Malonate salt of varlitinib - Google Patents

Malonate salt of varlitinib

Info

Publication number
SG11202104073XA
SG11202104073XA SG11202104073XA SG11202104073XA SG11202104073XA SG 11202104073X A SG11202104073X A SG 11202104073XA SG 11202104073X A SG11202104073X A SG 11202104073XA SG 11202104073X A SG11202104073X A SG 11202104073XA SG 11202104073X A SG11202104073X A SG 11202104073XA
Authority
SG
Singapore
Prior art keywords
varlitinib
malonate salt
malonate
salt
Prior art date
Application number
SG11202104073XA
Inventor
Robert Moore
Original Assignee
Aslan Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aslan Pharmaceuticals Pte Ltd filed Critical Aslan Pharmaceuticals Pte Ltd
Publication of SG11202104073XA publication Critical patent/SG11202104073XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202104073XA 2018-10-09 2019-10-09 Malonate salt of varlitinib SG11202104073XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201808900X 2018-10-09
PCT/SG2019/050504 WO2020076239A1 (en) 2018-10-09 2019-10-09 Malonate salt of varlitinib

Publications (1)

Publication Number Publication Date
SG11202104073XA true SG11202104073XA (en) 2021-05-28

Family

ID=68296623

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104073XA SG11202104073XA (en) 2018-10-09 2019-10-09 Malonate salt of varlitinib

Country Status (8)

Country Link
US (1) US20210379070A1 (en)
EP (1) EP3864014B1 (en)
JP (1) JP2022504201A (en)
KR (1) KR20210090625A (en)
CN (1) CN112969699A (en)
AU (1) AU2019359036A1 (en)
SG (1) SG11202104073XA (en)
WO (1) WO2020076239A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CN102432552B (en) * 2003-08-14 2016-01-20 阿雷生物药品公司 As the quinazoline analogs of receptor tyrosine kinase inhibitors
AU2007317296B2 (en) 2006-11-08 2012-07-05 Bristol-Myers Squibb Company Pyridinone compounds
MX2011003553A (en) 2008-10-02 2011-05-25 Respivert Ltd P38 map kinase inhibitors.
EP2177510A1 (en) * 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
ES2788162T3 (en) * 2015-09-04 2020-10-20 Aslan Pharmaceuticals Pte Ltd Varlitinib for use in the treatment of resistant or refractory cancer
KR102627044B1 (en) * 2015-10-19 2024-01-18 선샤인 레이크 파르마 컴퍼니 리미티드 Salts of EGFR inhibitors, their crystalline forms and uses
CN105461729B (en) * 2015-11-18 2017-12-05 乳源瑶族自治县大众药品贸易有限公司 A kind of salt of EGFR inhibitor, crystal formation and application thereof
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method

Also Published As

Publication number Publication date
KR20210090625A (en) 2021-07-20
US20210379070A1 (en) 2021-12-09
JP2022504201A (en) 2022-01-13
AU2019359036A1 (en) 2021-06-03
CN112969699A (en) 2021-06-15
EP3864014A1 (en) 2021-08-18
EP3864014C0 (en) 2023-07-05
WO2020076239A1 (en) 2020-04-16
EP3864014B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
IL264521A (en) Solid state forms of lumateperone ditosylate salt
GB201806072D0 (en) Methods of manufacture
IL276592A (en) Derivatives of sobetirome
PL3532457T3 (en) Crystalline forms of hydroxynorketamine
EP3894768C0 (en) Methods of cryo-curing
IL268221B (en) Ethane-sulfonate salt of quinoline derivative
GB201805904D0 (en) Methods of Manufacture
IL269792B (en) Crystalline forms of (s)-afoxolaner
IL277578A (en) Novel salt forms of urat-1 inhibitors
IL276107A (en) Solid forms of fasoracetam
IL278549B2 (en) Intermediates and processes for the preparation of linagliptin and its salts
SG11201704431VA (en) Novel salt of fused pyrimidine compound and crystal thereof
SG11202105136WA (en) Application of chidamide
SG11202104073XA (en) Malonate salt of varlitinib
GB201809460D0 (en) Salt form
GB201809458D0 (en) Salt form
IL283421A (en) Solid state forms of reproxalap
ZA202100765B (en) Crystalline epinephrine malonate salt
PT3901141T (en) Novel form of isoquinolinesulfonamide
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound
IL270937A (en) Crystalline forms of seletalisib
GB201810835D0 (en) Methods of use
GB201801181D0 (en) Method of use
GB201721386D0 (en) Chrondogy of time-wave
PL3511335T3 (en) Manufacture of metallasilisesquioxanes